Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2012 3
2013 3
2014 2
2016 4
2017 3
2018 4
2019 7
2020 7
2021 13
2022 14
2023 19
2024 21
2025 28
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bckd (142 results)?
BCKDK regulates breast cancer cell adhesion and tumor metastasis by inhibiting TRIM21 ubiquitinate talin1.
Xu C, Yang K, Xuan Z, Li J, Liu Y, Zhao Y, Zheng Z, Bai Y, Shi Z, Shao C, Zhang L, Sun H. Xu C, et al. Cell Death Dis. 2023 Jul 17;14(7):445. doi: 10.1038/s41419-023-05944-4. Cell Death Dis. 2023. PMID: 37460470 Free PMC article.
However, the relevance of BCKDK to the development and progression of breast cancers and its function is unclear. This study found that BCKDK was overexpressed in breast cancer, associated with poor prognosis, and implicated in tumor metastasis. ...
However, the relevance of BCKDK to the development and progression of breast cancers and its function is unclear. This study found th …
Targeting the BCKDK/BCLAF1/MYC/HK2 axis to alter aerobic glycolysis and overcome Trametinib resistance in lung cancer.
Wu H, Yang J, Yang Z, Xiao Y, Liu R, Jia J, Zhang X, Zhang Y, Fu Z, Yao Z, Lv J. Wu H, et al. Cell Death Differ. 2025 Dec;32(12):2210-2224. doi: 10.1038/s41418-025-01531-6. Epub 2025 May 29. Cell Death Differ. 2025. PMID: 40442441
However, the role of BCKDK in lung cancer remains largely unexplored. In this study, we explored the mechanisms by which BCKDK influences lung cancer progression and contributes to drug resistance. ...Targeting BCKDK in combination with Trametinib may offer a …
However, the role of BCKDK in lung cancer remains largely unexplored. In this study, we explored the mechanisms by which BCKDK …
BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease.
Jishi A, Hu D, Shang Y, Wang R, Gunzler SA, Qi X. Jishi A, et al. Acta Neuropathol Commun. 2024 Dec 21;12(1):198. doi: 10.1186/s40478-024-01915-8. Acta Neuropathol Commun. 2024. PMID: 39709505 Free PMC article.
Mechanistically, BCKDK interacts with the NDUFS1 subunit of Complex I to stabilize its function. Loss of BCKDK disrupts this interaction, leading to Complex I destabilization and enhanced alphaSyn aggregation. ...Similarly, in patient-derived iPS cells differentiate …
Mechanistically, BCKDK interacts with the NDUFS1 subunit of Complex I to stabilize its function. Loss of BCKDK disrupts this i …
BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism.
Yang Q, Zhu X, Huang P, Li C, Han L, Han Y, Gan R, Xin B, Tu Y, Zhou S, Yuan T, Hao J, Li C, Zhang L, Shi L, Guo C. Yang Q, et al. Mol Ther. 2024 Sep 4;32(9):3128-3144. doi: 10.1016/j.ymthe.2024.05.017. Epub 2024 May 11. Mol Ther. 2024. PMID: 38734897 Free PMC article.
BCKDK overexpression (OE) in CAR-T cells significantly improved cancer cell lysis, while BCKDK knockout (KO) resulted in inferior lysis potential. ...In conclusion, BCKDK-engineered CAR-T cells exert a distinct phenotype for superior anticancer efficiency....
BCKDK overexpression (OE) in CAR-T cells significantly improved cancer cell lysis, while BCKDK knockout (KO) resulted in infer …
The BCKDK inhibitor BT2 is a chemical uncoupler that lowers mitochondrial ROS production and de novo lipogenesis.
Acevedo A, Jones AE, Danna BT, Turner R, Montales KP, Benincá C, Reue K, Shirihai OS, Stiles L, Wallace M, Wang Y, Bertholet AM, Divakaruni AS. Acevedo A, et al. J Biol Chem. 2024 Mar;300(3):105702. doi: 10.1016/j.jbc.2024.105702. Epub 2024 Jan 30. J Biol Chem. 2024. PMID: 38301896 Free PMC article.
The branched-chain ketoacid dehydrogenase kinase (BCKDK) inhibitor BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) is often used in preclinical models to increase BCAA oxidation and restore steady-state BCAA and branched-chain alpha-ketoacid levels. BT2 administratio …
The branched-chain ketoacid dehydrogenase kinase (BCKDK) inhibitor BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) is often use …
Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression.
Wang W, Li Y, Tang L, Shi Y, Li W, Zou L, Zhang L, Cheng Y, Yuan Z, Zhu F, Duan Q. Wang W, et al. Cancer Lett. 2024 Jun 1;591:216849. doi: 10.1016/j.canlet.2024.216849. Epub 2024 Apr 16. Cancer Lett. 2024. PMID: 38621458 Free article.
We found that BCAT1 is phosphorylated by branched chain ketoacid dehydrogenase kinase (BCKDK) at S5, S9, and T312, which increases its catalytic and antioxidant activity and stability. ...In addition, we demonstrate through in vivo and in vitro experiments that BCAT1 phosp …
We found that BCAT1 is phosphorylated by branched chain ketoacid dehydrogenase kinase (BCKDK) at S5, S9, and T312, which increases it …
Nuclear-Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance.
Liu H, Feng J, Pan T, Zhang P, Ye L, Jiang Z, Zhou Z, Mao Q, Li J, Yang X, Gao P, Huang D, Zhang H. Liu H, et al. Adv Sci (Weinh). 2025 Jun;12(22):e2416590. doi: 10.1002/advs.202416590. Epub 2025 Apr 29. Adv Sci (Weinh). 2025. PMID: 40298908 Free PMC article.
Notably, aberrant expression of the BCKDK/p-RNF8/RAD51 axis correlates with breast cancer progression and poor patient survival. Furthermore, this work identifies a small molecule inhibitor of BCKDK, GSK180736A, that disrupts its HRR function and exhibits strong tum …
Notably, aberrant expression of the BCKDK/p-RNF8/RAD51 axis correlates with breast cancer progression and poor patient survival. Furt …
BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening.
Tangeraas T, Constante JR, Backe PH, Oyarzábal A, Neugebauer J, Weinhold N, Boemer F, Debray FG, Ozturk-Hism B, Evren G, Tuba EF, Ummuhan O, Footitt E, Davison J, Martinez C, Bueno C, Machado I, Rodríguez-Pombo P, Al-Sannaa N, De Los Santos M, López JM, Ozturkmen-Akay H, Karaca M, Tekin M, Pajares S, Ormazabal A, Stoway SD, Artuch R, Dixon M, Mørkrid L, García-Cazorla A. Tangeraas T, et al. Brain. 2023 Jul 3;146(7):3003-3013. doi: 10.1093/brain/awad010. Brain. 2023. PMID: 36729635
Branched-chain ketoacid dehydrogenase kinase (BCKDK) deficiency causes branched-chain amino acid (BCAA) depletion and is linked to a neurodevelopmental disorder characterized by autism, intellectual disability and microcephaly. ...In this cross-sectional study, patients wi …
Branched-chain ketoacid dehydrogenase kinase (BCKDK) deficiency causes branched-chain amino acid (BCAA) depletion and is linked to a …
BCKDK accelerates the progression of diabetic kidney disease by regulating leucine-mediated metabolic remodelling in renal tubular cells.
Shi C, Wang X, Qin S, He A, Wu X, Ke Q, Shen R, Wan Y, Wang L, Xiao Y, Liu D, Yu X, Shen X, Sheng Y, Zhu X, Jiang L, Zen K, Dai C, Zhou Y. Shi C, et al. Diabetologia. 2025 Dec;68(12):2879-2898. doi: 10.1007/s00125-025-06519-y. Epub 2025 Aug 16. Diabetologia. 2025. PMID: 40817934
Enhancement of leucine degradation was achieved through genetic ablation or pharmacological inhibition of branched-chain ketoacid dehydrogenase kinase (BCKDK). Cultured kidney tubular epithelial cells were used to analyse the underlying cellular mechanisms. ...RESULTS: Mea …
Enhancement of leucine degradation was achieved through genetic ablation or pharmacological inhibition of branched-chain ketoacid dehydrogen …
BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway.
Li H, Yu D, Li L, Xiao J, Zhu Y, Liu Y, Mou L, Tian Y, Chen L, Zhu F, Duan Q, Xue P. Li H, et al. J Oncol. 2022 Apr 22;2022:3691635. doi: 10.1155/2022/3691635. eCollection 2022. J Oncol. 2022. PMID: 35498541 Free PMC article.
RESULTS: We found that the expression of BCKDK was upregulated in OC tissues and the high expression of BCKDK was correlated with an advanced pathological grade in patients. The ectopic overexpression of BCKDK promoted the proliferation and migration of OC ce …
RESULTS: We found that the expression of BCKDK was upregulated in OC tissues and the high expression of BCKDK was correlated w …
125 results